Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diprosone ointment vasoconstriction dose-duration response study in healthy volunteers
ACTRN12623001179628Phase 4Completed
- Sponsor
- Zenith Technologies
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of betamethasone dipropionate in atopic dermatitis (AD) and psoriasis, sponsored by Zenith Technologies. Primary endpoints: ED50 parameter of Diprosone ointment and D1 parameter of Diprosone ointment. Started Dec 2023; status: completed.
02
Drugs
betamethasone dipropionate
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on ACTRN12623001179628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001179628.